BCAB logo

BCAB
BioAtla Inc

1,419
Mkt Cap
$6.01M
Volume
18,340.00
52W High
$71.50
52W Low
$3.26
PE Ratio
-0.09
BCAB Fundamentals
Price
$3.44
Prev Close
$3.62
Open
$3.45
50D MA
$5.75
Beta
1.63
Avg. Volume
54,304.42
EPS (Annual)
-$50.66
P/B
-0.16
Rev/Employee
$48,780.49
$36.62
Loading...
Loading...

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available

Earnings Recap

BioAtla expects near-term expenses to decrease due to workforce reduction and cost containment. BioAtla anticipates receiving $4.5M soon and $2M by August 1, 2026, from Context.

Bullish

BioAtla significantly reduced its net loss to -$6.3M in Q1 2026, driven by a 70% workforce reduction and cost containment. An amended Context License Agreement also secured $6.5M in payments for BioAtla.

Bearish

BioAtla faces substantial doubt about its ability to continue as a going concern, with ongoing strategic evaluations and clinical program delays. Commercialization risks and market receptiveness for its novel therapeutic modality remain significant challenges.

Latest BCAB News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.